View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 25, 2021updated 11 Jul 2022 2:22pm

CytoDyn treats first subject in Phase III Covid-19 trial of leronlimab

The Brazilian trial will enrol 316 critically ill Covid-19 patients in hospital and require supplemental oxygen.

CytoDyn has treated the first subject in the Phase III CD16 clinical trial of its chemokine receptor 5 (CCR5) antagonist, leronlimab, in critically ill Covid-19 patients in Brazil.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An experimental humanised Immunoglobulin G4 monoclonal antibody, leronlimab attaches to CCR5.

CCR5 is a cellular receptor vital in HIV infection, tumour metastases and a variety of other ailments such as nonalcoholic steatohepatitis.

The Phase III trial will enrol Covid-19 patients who are critically ill, admitted to the hospital and need mechanical and invasive ventilation or extracorporeal membrane oxygenation (ECMO).

Being carried out at 29 hospitals, the trial will have 316 subjects who will receive either four intravenous (IV) doses or 700mg leronlimab weekly or a placebo.

Following the recruitment of 127 subjects, an interim analysis will be carried out 28 days later.

Furthermore, the company plans to seek an Emergency Use Authorization on concluding this interim analysis, based on prior robust sub-population assessment in the CD12 trial.

CytoDyn president and CEO Nader Pourhassan said: “We are seeing strong optimism from all of the doctors and individuals involved in this project, especially since the primary endpoint for CD16 is similar to an endpoint in our past CD12 trial, which produced 166% better results in the leronlimab arm versus placebo.

“Importantly, this trial provides for two additional doses and delivery via IV (which allows leronlimab absorption to occur within one-two hours of being administered compared to two-three days when administered via SQ).”

Last month, CytoDyn treated the first subject in another Phase III CD17 trial in Brazil.

An interim assessment in this trial will be carried out 28 days following the enrolment of 245 subjects.

In August, CytoDyn received approval from Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA) to commence patient enrolment in a Phase III CD17 trial of leronlimab in severe Covid-19 patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena